Ex Parte Chen - Page 6


                  Appeal No.  2006-3290                                                              Page 6                    
                  Application No.  10/072,823                                                                                  
                          Appellant asserts that ‘016, ‘434, Son or Ito do not teach the type of                               
                  cancer that can be treated with the compound or extract.  Brief, pages 5-6.5                                 
                  However, as discussed above, there is no requirement in Appellant’s claim 1 that                             
                  cancer generally or any particular type of cancer be treated.  As set forth in In re                         
                  Pearson, 494 F.2d 1399, 1403, 181 USPQ 641, 644 (CCPA 1974), “terms [that]                                   
                  merely set forth the intended use for ... an otherwise old composition ... do not                            
                  differentiate the claimed composition from those known in the prior art.”  The                               
                  Pearson court explained that “[i]t seems quite clear to us that one of the                                   
                  compositions admitted to be old by the appellant would not undergo a                                         
                  metamorphosis to a new composition by labeling its container to show that it is a                            
                  composition suitable for [another use].”  Id.  The evidence of record establishes                            
                  that both oridonin and lupulone are individually effective for the treatment of                              
                  gastrointestinal disorders (stomachache). See ‘016, page 1 (oridonin) and                                    
                  Matsui, page 10 (lupulone).  Accordingly, we find that the evidence of record                                
                  establishes that a person of ordinary skill in the art would have been motivated to                          
                  combine oridonin and lupulone into a composition for the treatment of                                        
                  gastrointestinal disorders.  See Kerkhoven, Susi, and Crockett.                                              
                          Nevertheless, since the record before us is focused on the combination of                            
                  the references for the treatment of cancer we will address this issue.  Appellant                            
                  contends that “[t]he cited references do not provide the motivation to combine                               
                  oridonin and lupulone to treat the same types of cancers, let alone breast and                               
                                                                                                                               
                  5 Appellant recognizes that ‘016, ‘434, Son and Ito do not teach the treatment of any particular             
                  cancer.  Nevertheless, Appellant asserts (Brief, page 9), “[b]ased on the references cited by the            
                  Examiner, there appears to be no overlap between the cancer-type specificity of oridonin and                 
                  lupulone.”  What is unclear on this record is how Appellant can reach this conclusion when she               
                  recognizes that four of the five references relied upon teach a non-specific anti-cancer activity.           




Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  Next

Last modified: September 9, 2013